Subsidiary of Shanghai Haohai Biological Technology (688366.SH) obtains a medical device registration certificate for multifocal aspheric artificial intraocular lens products.
Haohai Life Sciences (688366.SH) announced that its wholly-owned subsidiary, Henan Universe Artificial Intraocular Lens Research Co., Ltd., recently received the "Medical Device Registration Certificate of the People's Republic of China" issued by the National Medical Products Administration for its multifocal non-spherical intraocular lens products.
Shanghai Haohai Biological Technology (688366.SH) announced that its wholly-owned subsidiary, Henan Universe Artificial Crystalline Lens Development Co., Ltd., has recently received the "Medical Device Registration Certificate of the People's Republic of China" issued by the National Medical Products Administration for its multifocal non-ellipsoidal artificial crystalline lens product.
This product is the world's first multifocal artificial crystalline lens based on the patented technology of FOURSEMI harmonic five-focus diffractive artificial crystalline lens, which can achieve more efficient distribution of light energy, improve light energy utilization, enhance the intermediate vision of traditional three-focus artificial crystalline lenses, and make the vision in the far-intermediate area, intermediate distance area, and intermediate-close area more consistently smooth.
Related Articles

CITIC (00267): CITIC Metal Co., Ltd's initial public offering of restricted shares will start trading on April 10th.

Estun Automation (02715): Stable Price Action, End of Stable Price Period, and Expiry of Oversubscription Rights

BOSS ZHIPIN-W (02076) spent 3.9941 million US dollars to repurchase 588,800 shares on April 6th.
CITIC (00267): CITIC Metal Co., Ltd's initial public offering of restricted shares will start trading on April 10th.

Estun Automation (02715): Stable Price Action, End of Stable Price Period, and Expiry of Oversubscription Rights

BOSS ZHIPIN-W (02076) spent 3.9941 million US dollars to repurchase 588,800 shares on April 6th.

RECOMMEND

Hong Kong Stocks Surge! Buying Opportunity Or Wait And See? Analysts Provide Comprehensive Interpretation
02/04/2026

Narrative Drives Everything As China’s AI Newcomers Enter An Era Of Extreme Volatility, Retail Investors Flood In
02/04/2026

Fund Cohort Stocks Rally As Institutional Confidence In Hong Kong Equities Shows Signs Of Repair
02/04/2026


